Figure 7

Glibenclamide combination with antineoplasic drugs. MDA-MB-231 cell proliferation was evaluated by counting of colonies with 50 cells or more and expressed as percentage of controls (means ± SEM of three independent experiments). Panel A: Results obtained with tamoxifen (Tam) 0.1, 0.5, 1 or 5 μM. Panel C: Inhibition of proliferation obtained with doxorubicin (Dox) 0.01, 0.05, 0.1 or 0.5 nM. Panel B and D: Results obtained for combination of 25 μM Gli plus different concentrations of Tam or Dox. Panel A and C: *p < 0.05 vs. control; **p < 0.01 vs. control; ***p < 0.001 vs. control, ANOVA and Dunnet post test. Panel B: p: NS vs. Gli 25 μM, t test. Panel D: *p < 0.05 vs. Dox 0.01 nM, vs. Dox 0.1 nM; **p < 0.001 vs Dox 0.05 nM; ⁺p < 0.05 vs. Dox 0.05 nM + Gli 25 μM; ⁺⁺p < 0.001 vs. Dox 0.1 nM + Gli 25 μM. One way ANOVA and Tuckey post test.